Copper and Zinc Dysregulation in Alzheimer's Disease

Stefano L Sensi, Alberto Granzotto, Mariacristina Siotto, Rosanna Squitti

Research output: Contribution to journalReview articlepeer-review


Alzheimer's disease (AD) is one of the most common forms of dementia. Despite a wealth of knowledge on the molecular mechanisms involved in AD, current treatments have mainly focused on targeting amyloid β (Aβ) production, but have failed to show significant effects and efficacy. Therefore, a critical reconsideration of the multifactorial nature of the disease is needed. AD is a complex multifactorial disorder in which, along with Aβ and tau, the convergence of polygenic, epigenetic, environmental, vascular, and metabolic factors increases the global susceptibility to the disease and shapes its course. One of the cofactors converging on AD is the dysregulation of brain metals. In this review, we focus on the role of AD-related neurodegeneration and cognitive decline triggered by the imbalance of two endogenous metals: copper and zinc.

Original languageEnglish
Pages (from-to)1049-1063
Number of pages15
JournalTrends in Pharmacological Sciences
Issue number12
Publication statusPublished - Dec 2018


  • Alzheimer Disease/etiology
  • Animals
  • Brain/metabolism
  • Copper/metabolism
  • Humans
  • Zinc/metabolism


Dive into the research topics of 'Copper and Zinc Dysregulation in Alzheimer's Disease'. Together they form a unique fingerprint.

Cite this